Arrowhead Pharmaceuticals Faces Pivotal Week with Key FDA Decision and Earnings Report

Investor attention is firmly fixed on Arrowhead Pharmaceuticals this week as the biotechnology firm approaches two significant milestones that could dramatically influence its trajectory. With the stock having surged more than 85% since the start of the year, the market is questioning whether this momentum can be sustained or if the company is poised for a setback.

Financial Health and Strategic Partnerships in Focus

Before the market opens on November 25, Arrowhead is scheduled to release its full-year financial results. Market experts are projecting earnings of $0.13 per share for the most recent quarter. A critical point of analysis will be the company’s cash position. Management has previously indicated that its existing liquid assets are sufficient to fund operations through 2028. Furthermore, investors will be scrutinizing the strategic alliances with industry giants Novartis and the milestone payments received from Sarepta Therapeutics, which provide a steady revenue stream and mitigate financial risk.

All Eyes on the FDA for Plozasiran Verdict

The most immediate and potentially impactful event is the U.S. Food and Drug Administration’s verdict on Plozasiran, expected tomorrow, November 18. This therapeutic candidate, designed to treat the rare genetic condition familial chylomicronemia syndrome (FCS), represents a landmark opportunity for Arrowhead. A successful approval would not only mark its first independently marketed drug but also serve as a powerful validation of the company’s proprietary RNAi technology. The decision is highly anticipated following encouraging data from the Phase 3 PALISADE clinical trial.

Should investors sell immediately? Or is it worth buying Arrowhead?

A Robust Pipeline Beyond a Single Candidate

Arrowhead’s potential extends well beyond Plozasiran. The company is concurrently advancing several other drug candidates through late-stage trials, including Zodasiran and Fazirsiran. The strength of its TRiM™ platform is further evidenced by recent business developments, such as a new collaboration with Novartis for ARO-SNCA that included a $100 million payment from Sarepta. These partnerships underscore the external confidence in Arrowhead’s research capabilities and contribute significantly to its financial stability.

The outcomes of this decisive week will ultimately determine if Arrowhead Pharmaceuticals can continue its impressive run or if it will face a period of recalibration following the high-stakes regulatory and financial announcements.